^
Association details:
| Biomarker: | IDH1 R132H |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor) + LY3410738 (IDH1 inhibitor, IDH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 6417: LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML)
Published date:
06/23/2020
Excerpt:
In addition, since IDH1 mutant AML cells have been shown to strongly depend on the anti-apoptotic Bcl-2 for the survival, we also combined LY3410738 with FDA approved Bcl-2 inhibitor, venetoclax. In vitro, isogenic cells with IDH1R132H mutation were more sensitive to the combination than wild-type IDH1-expressing cells....In conclusion, LY3410738 exhibits enhanced efficacy in IDH1 mutant AML PDX models in combination with Cytarabine, Azacitidine, Midostaurin and Venetoclax and demonstrates improved potency and durability compared to Ivosidenib.
Secondary therapy:
cytarabine + azacitidine
DOI:
10.1158/1538-7445.AM2020-6417
